CRMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
CorMedix Inc (CRMD) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has shown some positive developments, such as an analyst raising the price target and positive Phase 3 results for Rezzayo, the technical indicators and options data suggest a neutral to slightly bearish sentiment. Additionally, there are no strong trading signals or recent news catalysts to support an immediate buy decision.
The MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 55.897, and moving averages are converging, showing no clear trend. Support and resistance levels suggest limited upside potential in the short term, with key resistance at 8.98 and support at 8.404.
An analyst from RBC Capital raised the price target to $14 from $13, citing positive Phase 3 results for Rezzayo, which is competitive in its market with broad-spectrum activity and favorable tolerability.
No significant trading trends from hedge funds or insiders. Technical indicators do not show a strong bullish signal. Options data indicates a bearish sentiment with a high put-call volume ratio of 14.12.
No financial data available for analysis.
RBC Capital maintains an Outperform rating with a raised price target of $14, reflecting optimism about the company's product pipeline.
